Login to Your Account

Deals And M&A NEWS

Three months after nabbing Kite Pharma Inc. for $11.9 billion, Gilead Sciences Inc. fine-tuned its cell therapy strategy with the structured acquisition of privately held Cell Design Labs Inc.

Carmot Therapeutics Inc., a small-molecule lead-identification specialist and partner of Amgen Inc. since 2014, is extending its work for the Thousand Oaks, Calif.-based drugmaker to Parkinson's disease (PD) and other selected areas in a new multiyear deal. 

Australia's CSL Ltd. said it expects to spend between $450 million and $550 million on its largest-ever study, a phase III trial of CSL-112, an I.V. infusion formulation of human apolipoprotein A-I intended to reduce early recurrent cardiovascular events in heart attack survivors.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: